<?xml version="1.0" encoding="UTF-8"?>
<p id="par0040">Currently, the collection process and transfusion of plasma derived from patients who have fully recovered from COVID-19 is of wide spread interest both nationally and internationally as the development of the infection and its propagation are pandemic. Therefore, using neutralizing anti-COV-2 immunoglobulins that are present in COVID-19 convalescent plasma is logically an interesting targeted therapeutic approach, acting on the foundation of the well-established concept of passive immunotherapy.</p>
